Anti-TMEM106B antibodies and methods of use thereof

US12319734B2 · kind B2 · utility

Assignee

• Alector LLC

Inventors

• Arnon Rosenthal · Woodside, US
• Eric J. Brown · San Francisco, US
• Tina SCHWABE · San Francisco, US
• Angie Yee · San Francisco, US
• Herve Rhinn · New York, US

Key dates

• Filing date: Aug 18, 2022
• Grant date: Jun 3, 2025
• Expiry date: Sep 10, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.